Cargando…

Infiltrative growth pattern of prostate cancer is associated with lower uptake on PSMA PET and reduced diffusion restriction on mpMRI

PURPOSE: Recently, a significant association was shown between novel growth patterns on histopathology of prostate cancer (PCa) and prostate-specific membrane antigen (PSMA) uptake on [(68)Ga]PSMA-PET. It is the aim of this study to evaluate the association between these growth patterns and ADC (mm(...

Descripción completa

Detalles Bibliográficos
Autores principales:	Laudicella, Riccardo, Rüschoff, Jan H., Ferraro, Daniela A., Brada, Muriel D., Hausmann, Daniel, Mebert, Iliana, Maurer, Alexander, Hermanns, Thomas, Eberli, Daniel, Rupp, Niels J., Burger, Irene A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399036/ https://www.ncbi.nlm.nih.gov/pubmed/35435496 http://dx.doi.org/10.1007/s00259-022-05787-9

Ejemplares similares

What’s behind (68)Ga-PSMA-11 uptake in primary prostate cancer PET? Investigation of histopathological parameters and immunohistochemical PSMA expression patterns
por: Rüschoff, Jan H., et al.
Publicado: (2021)

Hot needles can confirm accurate lesion sampling intraoperatively using [(18)F]PSMA-1007 PET/CT-guided biopsy in patients with suspected prostate cancer
por: Ferraro, Daniela A., et al.
Publicado: (2021)

Immunohistochemical PSMA expression patterns of primary prostate cancer tissue are associated with the detection rate of biochemical recurrence with (68)Ga-PSMA-11-PET
por: Ferraro, Daniela A., et al.
Publicado: (2020)

(68)Ga-PSMA-11 PET/MRI versus multiparametric MRI in men referred for prostate biopsy: primary tumour localization and interreader agreement
por: Ferraro, Daniela A., et al.
Publicado: (2022)

Improved oncological outcome after radical prostatectomy in patients staged with (68)Ga-PSMA-11 PET: a single-center retrospective cohort comparison
por: Ferraro, Daniela A., et al.
Publicado: (2020)

Quantitative imaging parameters to predict the local staging of prostate cancer in intermediate- to high-risk patients
por: Laudicella, Riccardo, et al.
Publicado: (2022)

Diagnostic performance of (68)Ga-PSMA-11 PET/MRI-guided biopsy in patients with suspected prostate cancer: a prospective single-center study
por: Ferraro, Daniela A., et al.
Publicado: (2021)

Role of mpMRI of the prostate in screening for prostate cancer
por: Wallis, Christopher J. D., et al.
Publicado: (2017)

Correlation between genomic index lesions and mpMRI and (68)Ga-PSMA-PET/CT imaging features in primary prostate cancer
por: Kesch, Claudia, et al.
Publicado: (2018)

False-positive mpMRI and true-negative (68)Ga-PSMA PET/CT xanthogranulomatous prostatitis: a case report
por: Tang, Yongxiang, et al.
Publicado: (2022)

Mischievous malakoplakia: A potential pitfall of mpMRI of the prostate?
por: Rezaee, Michael E., et al.
Publicado: (2020)

The combined value of mpUS and mpMRI-TRUS fusion for the diagnosis of clinically significant prostate cancer
por: Zhang, Xin, et al.
Publicado: (2022)

Applications of Artificial Intelligence to Prostate Multiparametric MRI (mpMRI): Current and Emerging Trends
por: Bardis, Michelle D., et al.
Publicado: (2020)

Comparison of (68)Ga-PSMA-11 PET-CT with mpMRI for preoperative lymph node staging in patients with intermediate to high-risk prostate cancer
por: Zhang, Qing, et al.
Publicado: (2017)

Pearls and pitfalls in diagnosing prostate cancer using multiparametric MRI (mpMRI)
por: Joshi, JJ, et al.
Publicado: (2015)

Optimising preoperative risk stratification tools for prostate cancer using mpMRI
por: Reisæter, Lars A. R., et al.
Publicado: (2017)

Differential diagnosis of uncommon prostate diseases: combining mpMRI and clinical information
por: Han, Chao, et al.
Publicado: (2021)

Can We Predict Skeletal Lesion on Bone Scan Based on Quantitative PSMA PET/CT Features?
por: Laudicella, Riccardo, et al.
Publicado: (2023)

Histopathology-validated lesion detection rates of clinically significant prostate cancer with mpMRI, [(68)Ga]PSMA-11-PET and [(11)C]Acetate-PET
por: Sandgren, Kristina, et al.
Publicado: (2023)

Evaluation of the PI-RADS Scoring System for Classifying mpMRI Findings in Men with Suspicion of Prostate Cancer
por: Junker, Daniel, et al.
Publicado: (2013)

bpMRI and mpMRI for detecting prostate cancer: A retrospective cohort study
por: Pan, Yongsheng, et al.
Publicado: (2023)

AI-predicted mpMRI image features for the prediction of clinically significant prostate cancer
por: Li, Song, et al.
Publicado: (2023)

Frequency and intensity of [(18)F]-PSMA-1007 uptake after COVID-19 vaccination in clinical PET
por: Maurer, Alexander, et al.
Publicado: (2022)

Intraindividual comparison between (68)Ga-PSMA-PET/CT and mpMRI for intraprostatic tumor delineation in patients with primary prostate cancer: a retrospective analysis in 101 patients
por: Spohn, Simon, et al.
Publicado: (2020)

Comparison of (68)Ga-PSMA-617 PET/CT with mpMRI for the detection of PCa in patients with a PSA level of 4–20 ng/ml before the initial biopsy
por: Li, Yu, et al.
Publicado: (2020)

Case report: PSMA PET/CT addresses the correct diagnosis in a patient with metastatic prostate cancer despite negative core biopsies and mpMRI. A diagnostic challenge
por: Vetrone, Luigia, et al.
Publicado: (2023)

Analysis of the cause of missed diagnosis in mpMRI/TRUS fusion-guided targeted prostate biopsy
por: Zhang, Fan, et al.
Publicado: (2022)

The role of mpMRI in qualification of patients with ISUP 1 prostate cancer on biopsy to radical prostatectomy
por: Nyk, Łukasz, et al.
Publicado: (2021)

Dynamic Contrast-Enhanced Study in the mpMRI of the Prostate—Unnecessary or Underutilised? A Narrative Review
por: Guljaš, Silva, et al.
Publicado: (2023)

Immunohistochemical Expression Pattern of Theragnostic Targets SSTR2 and PSMA in Endolymphatic Sac Tumors: A Single Institution Case Series
por: Brada, Muriel D., et al.
Publicado: (2022)

Identification of Urine Biomarkers to Improve Eligibility for Prostate Biopsy and Detect High-Grade Prostate Cancer
por: Alijaj, Nagjie, et al.
Publicado: (2022)

Transrectal Ultrasound in Prostate Cancer: Current Utilization, Integration with mpMRI, HIFU and Other Emerging Applications
por: Panzone, John, et al.
Publicado: (2022)

External validation of two mpMRI-risk calculators predicting risk of prostate cancer before biopsy
por: Pallauf, Maximilian, et al.
Publicado: (2022)

Development and external validation of a multivariable [(68)Ga]Ga-PSMA-11 PET-based prediction model for lymph node involvement in men with intermediate or high-risk prostate cancer
por: Muehlematter, Urs J., et al.
Publicado: (2023)

Negative mpMRI Rules Out Extra-Prostatic Extension in Prostate Cancer before Robot-Assisted Radical Prostatectomy
por: Dinneen, Eoin, et al.
Publicado: (2022)

Clash of the calculators: External validation of prostate cancer risk calculators in men undergoing mpMRI and transperineal biopsy
por: Wei, G., et al.
Publicado: (2021)

Non-timely clinically applicable ADC ratio in prostate mpMRI: a comparison with fusion biopsy results
por: Falaschi, Zeno, et al.
Publicado: (2022)

Developing a predictive model for clinically significant prostate cancer by combining age, PSA density, and mpMRI
por: Ma, Zengni, et al.
Publicado: (2023)

Microvascular proliferation is associated with high tumour blood flow by mpMRI and disease progression in primary prostate cancer
por: Børretzen, Astrid, et al.
Publicado: (2023)

Exploring the efficacy of multi-flavored feature extraction with radiomics and deep features for prostate cancer grading on mpMRI
por: Khanfari, Hasan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1g1qapae5ic0mss341faarifn0